Members of the House of Representatives are pushing for the next COVID-19 emergency package to include language giving cancer patients equal access to oral chemotherapy medications that can be taken at home.
Prior to the COVID-19 pandemic, NCI estimated that about 3% to 5% of adult cancer patients participated in clinical trials.
In the past decade, there has been a growing interest in capitalizing on advances in information technology to provide quality and patient-centered care to cancer patients and survivors outside a hospital or clinic setting.
On rare occasion, an innovator makes such a profound impact on the world that people thereafter cannot imagine what life was like before that transformation. Paradoxically, for those not witness to such an achievement, this phenomenon may have, in terms of legacy, a blunting effect.
The deal is off: Fox Chase Cancer Center will not be sold to Thomas Jefferson University.
The COVID-19 pandemic has been catastrophic to health care in the US.
The primary endpoint of overall survival was met in a phase III trial comparing the PD-1 inhibitor Libtayo (cemiplimab) to platinum-doublet chemotherapy in patients with first-line locally advanced or metastatic non-small cell lung cancer who tested positive for PD-L1 in ≥50% of tumor cells.
The phase III PROfound trial of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer who have a homologous recombination repair gene mutation and have progressed on prior treatment with new hormonal agent treatments (e.g. enzalutamide and abiraterone) has demonstrated improvement in overall survival.
GARNET study demonstrates potential of dostarlimab to treat recurrent or advanced endometrial cancer
The GARNET trial demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1) monoclonal antibody, provided clinically meaningful results in women with recurrent or advanced mismatch repair-deficient endometrial cancer who progressed on or after a platinum-based regimen.
